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Authors’ Reply
Authors’ reply to ‘Granulocytic myeloid-derived 
suppressor cells in peripheral blood of patients 
with cutaneous melanoma’
We are grateful to Dr Franklin and Dr Schilling for their inter-
est in our recent article (1) and we will try to respond to their 
constructive critical review.
In regard to Dr Franklin’s and Dr Schilling’s emphasis that 
the CD10–CD15+CD14–HLA-DR–/lowCD33lowCD11b+CD45low
CD16lowLin– panel is ‘… a widely used panel for identifying 
grMDSC in PBMC after density centrifugation’, we would like 
to underline that we initially conducted a pilot study show-
ing that cells with the above-mentioned phenotype copurified 
with the PBMC on density gradients (Supplementary Figure 1, 
available at International Immunology Online). The reasons 
why we decided to continue the study with lysed peripheral 
blood samples were listed in the article (1). We agree that the 
activated neutrophils can change their buoyancy and copu-
rify on a density gradient, but these activated cells are still 
CD10+ and the CD10 expression could even be up-regulated 
in activated mature neutrophils (2).
Regarding the remark on the separation of the grMDSC 
from eosinophils, besides being CD10–, eosinophils are also 
CD16–, CD45bright and high on side scatter (SSc) (3). Our tar-
geted population showed low, but positive CD16 expression, 
low CD45 expression and a low SSc position (1). Additionally, 
no eosinophilia was recognized in differential blood counts 
in our patients with >10% of the presumed grMDSC popu-
lation. Accordingly, we disagree with Dr Franklin’s and Dr 
Schilling’s assertion that we have distinguished eosinophils 
and grMDSC on the basis solely of low or absent CD16 
expression.
We agree that antigen expression changes with aging; 
however, both the grMDSC frequencies and the CD16 
expression intensity did not correlate with the patient’s age 
in our study. Subsequently, we detected CD66b on our 
grMDSC, which could separate them from immature myeloid 
cells, according to the results of Dumitru’s group, cited by Dr 
Franklin and Dr Schilling.
We agree that the functional assay is the most reliable 
evidence for immunosuppressive activity of certain cell 
populations; thus, we titled our manuscript as ‘A subpop-
ulation that may correspond to ...’ (1). On the other side, 
the classical suppressive assay can exclude neither the 
influence of activated healthy granulocytes, which are also 
capable of T-cell suppression (4), nor the possibility of 
MDSC activation during long-time cultivation with T cells 
(5). The suppressive assay is certainly superior in the situ-
ation of testing MDSC from the site of inflammation or the 
tumor-growing site, because those cells possess the imme-
diate capacity to down-regulate T-cell proliferation in vitro 
(5). Instead of using the classical suppressive assay, we 
identified our grMDSC by phenotype (1) and investigated 
possible in vivo grMDSC suppressive outcomes related to 
arginine depletion, oxidative stress and immune response 
skewing (Supplementary Figure 2, available at International 
Immunology Online).
At the end, we consider as a weakness of our study the fact 
that we have not performed repeated measurements of the 
grMDSC frequencies during the follow-up period.
Supplementary data
Supplementary data are available at International Immunology 
Online.
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